The ValenTx Endo Bypass System in Obese Subjects

NCT ID: NCT02954003

Last Updated: 2016-11-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-12-31

Study Completion Date

2018-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to collect clinical data to support the use of the ValenTx Endo Bypass System to improve weight loss and the resolution of comorbidities in obese subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Single-arm, non-randomized, open-label, multi-center trial conducted in up to 70 subjects to assess the safety and efficacy of the ValenTx Endo Bypass System over implant duration of up to 36 months.
* Body weight, adverse events and device function in implanted subjects will be monitored at monthly visits for the first year after implant, at quarterly visits during the second year, and biannually during the third year.
* Additional follow-up data will include vital signs, hip and waist circumference, blood lab tests, endoscopic assessments of the condition of the implanted device, and a quality of life questionnaire.
* All subjects will be followed for 12 months after device removal with scheduled visits at 1, 6 and 12 months after explant.
* Subject participation may last up to four years, but is expected to vary with implant duration, which will be determined on a case-by-case basis based on the condition of the implanted device.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Obesity Weight Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Endo Bypass

Subjects implanted with the investigational ValenTx Endo Bypass System

Group Type EXPERIMENTAL

Endo Bypass System

Intervention Type DEVICE

Subject is implanted with the device for up to 3 years.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Endo Bypass System

Subject is implanted with the device for up to 3 years.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ValenTx System

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Between 18- 60 years old.
2. BMI of 40-50 kg/m2 with or without comorbidities, BMI of 35-40 kg/m2 with one or more obesity related comorbidities, or BMI of 30-35 with type 2 diabetes
3. Willing to give informed consent, and able to understand what this means.
4. Documented failure with non-surgical weight loss methods.
5. Willing to follow the study procedures and comply with the visits schedule.
6. Live within a reasonable distance of the research center and be able to attend routine follow up visits.

Exclusion Criteria

1. Pregnancy or intention to become pregnant during the course of the study.
2. Abnormal screening esophagogastroduodenoscopy findings
3. Prior esophageal, gastric or bariatric surgery.
4. Known allergies to any of the device materials.
5. Use of weight loss drugs, stimulants and/or herbal weight loss supplements.
6. Recent or ongoing health conditions that contraindicate undergoing an elective weight loss procedure involving a device implanted within the lumen of the esophagus, stomach and proximal small intestine.
7. Participation in another clinical trial within 60 days of the implant.
8. Presence of psychiatric conditions that would impair the ability to provide informed consent or to comply with study procedures.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ValenTx, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Roland Maude-Griffin

Role: STUDY_DIRECTOR

ValenTx, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St. Joseph Healthcare

Hamilton, Ontario, Canada

Site Status

Hopital Laval (IUCPQ)

Québec, Quebec, Canada

Site Status

Hospital San Jose Tec de Monterrey

Monterrey, Nuevo León, Mexico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada Mexico

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EN 2.3

Identifier Type: -

Identifier Source: org_study_id